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An obligatory step of malaria parasite infection is
Plasmodium sporozoite invasion of host hepato-
cytes, and host lipoprotein clearance pathways have
been linked to Plasmodium liver infection. By using
RNA interference to screen lipoprotein-related host
factors, we show here that the class B, type I scaven-
ger receptor (SR-BI) is the strongest regulator of
Plasmodium infection among these factors. Inhibi-
tion of SR-BI function reduced P. berghei infection
in Huh7 cells, and overexpression of SR-BI led to
increased infection. In vivo silencing of liver SR-BI
expression in mice and inhibition of SR-BI activity
in human primary hepatocytes reduced infection
by P. berghei and by P. falciparum, respectively.
Heterozygous SR-BI+/ mice displayed reduced
P. berghei infection rates correlating with liver SR-BI
expression levels. Additional analyses revealed that
SR-BI plays a dual role in Plasmodium infection,
affecting both sporozoite invasion and intracellular
parasite development, and may therefore constitute
a good target for malaria prophylaxis.
INTRODUCTION
Malaria is a major global health problem, found most acutely in
Sub-Saharan Africa and in some parts of Asia and South Amer-
ica. Each year there are about 600 million new clinical cases and
at least one million individuals, mostly children, die from malaria
infections (Greenwood and Mutabingwa, 2002), all of which are
caused by the protozoan parasite Plasmodium. Moreover,
malaria represents a serious burden on the economic potential
of many countries in the world. Various attempts at eradicating
this disease have so far been unsuccessful, and in fact withinCell Hostthe last 10 to 15 years the burden of malaria has been increasing
(Greenwood and Mutabingwa, 2002), mainly because of the
emergence of P. falciparum variants that are resistant to the
drugs in use (Cunha-Rodrigues et al., 2006). These realities have
compounded the urgency of finding novel treatment strategies
that will be less vulnerable to the development of parasite resis-
tance, a goal that necessarily requires a better understanding of
the underlying parasite-host interactions.
After the bite of an infected mosquito delivers Plasmodium
sporozoites into a human host, the parasite first accumulates
in the liver, where it migrates through the cytoplasm of several
hepatocytes before invading the one in which it will develop
into an exoerythrocytic form (EEF) (Mota et al., 2001). During
this asymptomatic liver infection, the parasite proliferates and
changes from a motile sporozoite into thousands of merozoites
that will be released in the bloodstream and infect red blood
cells, initiating the clinical phase of infection. In doing so, its
exploitation of host liver resources represents an important and
as-yet underinvestigated vulnerability to prophylactic interven-
tion. In fact, although a single surviving EEF is sufficient to give
rise to a blood stage malaria infection, it has been shown that
even a small reduction in the liver parasite load can lead to an
even greater decrease in malaria severity (Alonso et al., 2005).
In this context, it is our main interest to identify and character-
ize the role of host factors that influence Plasmodium liver infec-
tion, as these may contribute to the design of rational interven-
tional strategies for the development of novel prophylactic
agents. To this end, we have established a high-throughput
assay system that, combined with high-content readouts using
automated microscopy, we have used for RNA interference
(RNAi) screening experiments. The present study was initiated to
follow up on observations from earlier reports that suggested a
link between host lipoprotein clearance pathways and Plasmo-
dium sporozoite infection of the liver (Shakibaei and Frevert,
1996; Sinnis et al., 1996). These reports have suggested a link
between hepatocyte invasion by sporozoites and apolipoprotein
clearance in the liver. However, from these reports, it was not& Microbe 4, 271–282, September 11, 2008 ª2008 Elsevier Inc. 271
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Host SR-BI in Malaria Parasite Liver InfectionFigure 1. RNAi Screen of Lipoprotein
Pathway Genes Identifies Host SR-BI as
Required for Infection of Huh7 Cells by
P. berghei Sporozoites
(A) Effects of 206 siRNA treatments targeting 53
lipoprotein pathway genes on Huh7 cell prolifera-
tion (x axis) and infection byP. berghei sporozoites
(y axis), both measured 24 hr after sporozoite
addition and 72 hr after siRNA transfection. Cell
proliferation was estimated as the percentage of
Huh7 nuclei relative to the mean from all experi-
mental wells on each plate. Infection rates were
calculated for each sample, as well as number of
EEFs:cell confluency (as described in main text),
also plotted here as a percentage relative to the
mean from all experimental wells on each plate.
For convenience, horizontal lines marking ± 2 SD
of the whole data set are also shown. Each circle
represents one siRNA (mean of triplicate values,
see also Table S1 for exact values). Negative con-
trols appear as blue and green circles, corre-
sponding to untreated cells and cells transfected
with a nonspecific control siRNA, respectively. Red
circles correspond to siRNAs targeting SR-BI.
(B) Same dataset as shown in (A), with each circle
representing one of the 53 tested genes, and
corresponding to the mean value from all siRNAs
targeting each gene. Color attributions are the
same as in (A).
(C) Comparison of effects of SR-BI siRNA treat-
ments on infection rate versus remaining mRNA
levels. Each circle represents one SR-BI siRNA
(mean of triplicate values). The horizontal gray
lines represent 2 SD from the mean infection rate
for entire data set.
(D) Effect of siRNA treatments on SR-BI protein levels in Huh7 cells, measured by semiquantitative western blotting of extracts taken at the time of infection, i.e.,
48 hr after siRNA transfection, from untransfected cells (Unt. C), cells transfected with a negative control nonspecific siRNA (Neg. C), or cells transfected with
human SR-BI-specific siRNAs (hSR-BI siRNAs). GAPDH was used as a loading control. Results were normalized to Neg. C levels (100%) and are expressed
as the mean ± SD of SR-BI expression levels in three independent samples.clear whether a lipoprotein receptor was involved in the infection
process or not. Thus, we sought to determine whether this was
the case, following an unbiased RNAi-based approach.
RESULTS
Host Scavenger Receptor BI Is Required
for P. berghei Infection of Huh7 Cells
We sought to analyze the role of lipoprotein pathway genes in
the liver stage of Plasmodium infection by applying an in vitro in-
fection assay in the context of a systematic RNAi-induced loss-
of-function screen. To this end, we assembled a library of 206
siRNAs targeting 53 genes expressed in the liver and annotated
as having validated or putative roles in lipoprotein assembly,
binding, or uptake (Table S1 available online). Each gene was tar-
geted with at least three distinct siRNA sequences, and each
siRNA was transfected individually into human Huh7 hepatoma
cells 24 hr after seeding, and, 48 hr later, cells were either in-
fected with freshly isolated P. berghei sporozoites or lysed for
quantitative RT-PCR (qRT-PCR) analysis of target mRNA knock-
down levels at the onset of infection (Figure S1). We then quan-
tified infection rates by fluorescence microscopy, using auto-
mated image analysis to count the number of stained EEFs,272 Cell Host & Microbe 4, 271–282, September 11, 2008 ª2008 Eland normalizing these values to cell confluency, as determined
by actin staining, to compensate for potential differences in total
cell surface available for infection in each well.
This library of siRNAs was screened in two independent runs,
generating phenotypic loss-of-function data and qRT-PCR anal-
ysis of remaining target mRNA levels (see detailed data in Table
S1). One gene, scavenger receptor BI (SR-BI), stood out from the
rest by showing significant reductions in infection rates with
three distinct siRNA sequences (Figure 1A, p < 0.001). This is
readily illustrated by plotting of the mean results from all siRNAs
for each targeted gene (Figure 1B). This effect on infection oc-
curred without any detectable side effects on cell proliferation,
as measured by nuclear counts (Figure 1A, Table S1). Impor-
tantly, the multiplicity of siRNA sequences underlying this result
argues strongly that the observed phenotype is indeed a specific
consequence of downregulating SR-BI expression and is not
arising through off-target effects (see Echeverri et al., 2006). As
further confirmation of specificity, the phenotypic severity (i.e.,
degree of inhibition of infection) was found to correlate well with
SR-BI knockdown, as quantified at the mRNA level by qRT-PCR
(Figure 1C), with four distinct SR-BI-targeting siRNA sequences
in multiple independent experiments. The SR-BI knockdown
was also confirmed at the protein level by quantitative westernsevier Inc.
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Host SR-BI in Malaria Parasite Liver Infectionblotting (Figure 1D). Together, these results strongly implicate
SR-BI as a key host molecule playing an important role during
Plasmodium infection of liver cells. It should be noted that the
present data does not rule out the possible involvement of other
genes among those tested here, as negative results in RNAi
screens are generally inconclusive (see Echeverri et al., 2006).
The implication of SR-BI was further validated by testing the
effects of known SR-BI inhibitors on infection, including a SR-
BI-blocking antibody (Silver, 2002) and several small synthetic
molecules previously reported to inhibit the SR-BI-mediated
selective uptake of lipids from HDL (termed ‘‘blockers of lipid
transport,’’ or BLTs [Nieland et al., 2002]). Addition of the SR-
BI-blocking antibody to cells 1 hr prior to sporozoite addition led
to a marked, dose-dependent decrease in infection rate as com-
pared to control samples, measured by the in vitro microscopy-
based Huh7 infection assay described above (Figure 2A).
Figure 2. Inhibition of Host SR-BI Protein
Function Reduces P. berghei Sporozoite
Infection of Huh7 Cells
Antibody and all compounds were added to Huh7
cells 1 hr before sporozoite addition, and infection
rates were measured 24 hr after sporozoite addi-
tion, by quantification of the number of EEFs, as
described in the main text. Results are expressed
as the mean ± SD of EEFs (%) in three independent
infections. Red symbols and lines represent the
mean levels of cell confluence based on auto-
mated analysis of actin staining, as measured for
each set of triplicate samples.
(A) Effect of a serial dilution of a SR-BI-blocking
antibody on P. berghei infection rate of Huh7 cells.
‘‘C1’’ indicates solvent-treated cells used as con-
trol. Cells treated with an irrelevant antibody
(anti-tubulin) were used also as control (‘‘C’’).
(B–D) Effect of known chemical inhibitors of SR-BI
(BLT-1, BLT-2, and BLT-4, respectively) used at
different concentrations on P. berghei infection
rate in Huh7 cells, as measured by quantification
of the number of EEFs. ‘‘C’’ indicates solvent-
treated cells used as negative control. The chem-
ical formula of each chemical inhibitor is also
presented.
(E) Effect of different concentrations of the iso-
structural, but essentially inactive, semicarbazone
derivative of BLT-1 (BLT-1sc) on P. berghei in-
fection rate in Huh7 cells, as measured by quanti-
fication of the number of EEFs. ‘‘C’’ indicates
solvent-treated cells used as negative control.
The chemical formula of the compound is also
presented.
Although the blocking antibody used
also targets SR-BII (a splicing variant of
the same gene), the results from the
screen clearly show that knockdown of
SR-BII does not lead to any effect on in-
fection (Table S1). This further supports
the notion that SR-BI alone accounts for
the effects observed in this antibody
blocking assay. Similar dose-dependent
decreases in P. berghei sporozoite infec-
tion rates were observed when cells were similarly incubated
with BLT-1, BLT-2, or BLT-4 throughout the 24 hr infection pe-
riod, showing IC50 values of 0.9, 5.2, and 19.9 mM, respectively
(Figures 2B–2D). Importantly, incubation of the cells with the iso-
structural, but essentially inactive, semicarbazone derivative of
BLT-1 (BLT-1sc), recently shown to be ineffective in inhibiting
SR-BI (Nieland et al., 2008), had no effect on infection (Figure 2E),
lending further support to SR-BI’s role in these infection assays.
As can be expected from the quite distinct assays and experi-
mental system used here, these values differ from the multiple
corresponding IC50 measurements published previously for
these compounds, looking at various other activities (Nieland
et al., 2002). It is nonetheless notable that the relative efficiencies
with which the different BLT compounds inhibited sporozoite in-
fection closely mirror their previously reported effects on the se-
lective uptake of lipids, with BLT-1 being two to five times and
Cell Host & Microbe 4, 271–282, September 11, 2008 ª2008 Elsevier Inc. 273
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thus suggesting a possible structural link between the two activ-
ities. Importantly, infection rates were not affected by preincuba-
tion of Plasmodium sporozoites with BLT-1 for 1 hr prior to addi-
tion to cells, showing that BLT-1 has no effect on sporozoite
viability (data not shown).
In sum, although we fully expect that each of the different
reagents used here carry different specificity ‘‘footprints,’’ the
high reproducibility of the observed phenotypes in our assays
using multiple distinct siRNAs, several synthetic compound
inhibitors, and a blocking antibody clearly support a causality
linked to the single target common to all of these, i.e., SR-BI.
Thus, altogether, the results strongly indicate a clear role for
SR-BI during P. berghei sporozoite infection of Huh7 cells.
SR-BI Plays a Role in P. berghei In Vivo Infection and in
P. falciparum Infection of Human Primary Hepatocytes
Because the above experiments were all performed in vitro with
the human hepatoma cell line Huh7, we sought to validate the
role of SR-BI in Plasmodium infection under more physiologically
relevant conditions. To this end, we first confirmed that inhibition
of SR-BI also leads to a reduction in P. berghei infection of
primary mouse hepatocytes (Figure S2, p < 0.001).
Next, we also confirmed the relevance of these findings in vivo,
using systemically delivered, liposome-formulated siRNAs to
silence SR-BI expression in adult mice and subjecting these to
infection by P. berghei sporozoites. Here, we used a qRT-PCR-
based assay to quantify infection rates by measuring levels of
Plasmodium 18S RNA found within extracts of liver samples har-
vested 40 hr after intravenous (i.v.) sporozoite injection. As for all
RNAi analyses, the gene specificity of RNAi-induced phenotypes
was extensively controlled in the present in vivo experiments.
This first included the parallel treatment of mice with a negative
control ‘‘nontargeting’’ siRNA (targeting a transcript that is not
expressed in these mice, in this case luciferase) to detect se-
quence-independent off-target effects. Sequence-dependent
off-target effects were addressed by testing of multiple distinct
siRNA sequences targeting SR-BI.
In vivo RNAi treatments have previously yielded potent gene-
specific knockdowns in rodent livers with stable lipid nanopar-
ticles (Akinc et al., 2008). In our experiments, SR-BI expression
was also reduced successfully in adult mouse livers with three
distinct SR-BI-specific siRNAs, each of which yielded 25%–
45% remaining SR-BI mRNA, as measured by qRT-PCR of tis-
sue extracts taken 76 hr after a single i.v. injection and normali-
zation to SR-BI mRNA levels in the livers of adult mice treated
with control siRNA (Figure 3A, p < 0.001, gray bars). This silenc-
ing was also confirmed at the protein level by semiquantitative
western blotting of corresponding liver extracts (Figure S3, p <
0.01) and at the physiological level by confirmation of the in-
creased blood cholesterol level that is expected from lowered
SR-BI function (Figure S4).
Compared to control siRNA treatments, this administration of
different SR-BI-specific siRNAs resulted in a significant reduc-
tion of liver infection by P. berghei sporozoites, yielding 30%–
50% of control infection loads, as measured by qRT-PCR of
P. berghei 18S rRNA in samples taken 40 hr after sporozoite in-
jection (Figure 3A, p < 0.001, black bars). In a parallel experiment,
mice treated with one of the SR-BI siRNAs also showed a reduc-274 Cell Host & Microbe 4, 271–282, September 11, 2008 ª2008 Elstion in the number of parasites reaching the bloodstream, com-
pared to their controls (Figure 3B, p < 0.05). Although by day 4
after sporozoite injection, all mice in the control group were pos-
itive for blood stages, only two out of five mice were positive in
the group pretreated with SR-BI siRNA (Figure 3B).
As further confirmation that the observed effects on infection
were due to SR-BI loss of function and were not indirect conse-
quences of unspecific toxicities possibly triggered by the siRNA
treatments, extensive analyses of tissue and serum markers for
activation of the interferon response pathway and a broad range
of toxicities clearly showed that the present SR-BI siRNA treat-
ments did not cause any pronounced effects of these types,
and any reproducible individual changes failed to correlate
with our Plasmodium infection results (Figures S5, S6, and S7).
Finally, it is also noted that the siRNA formulation and delivery
methodology used here was recently shown to yield no detecti-
ble disruption of the endogenous microRNA pathway (John
et al., 2007).
Next, we sought to test the strong prediction from the above
data that transgenic mice engineered to be SR-BI-deficient
should also show decreased liver infection rates. The results
from such mice required careful analysis because homozygous
SR-BI/ mice have recently been shown to exhibit clear signs
of oxidative stress, including elevated expression of several
genes such as heme oxigenase 1 (HO-1) (Van Eck et al., 2007).
Interestingly, we have recently shown that HO-1 plays a key
role in malaria-associated pathology during the blood stages of
infection (Pamplona et al., 2007). More directly relevant for the
present study, we have also found that as little as a 2-fold over-
expression of HO-1 in mouse liver in vivo can lead to an 8-fold
increase in liver infection by P. berghei sporozoites (Epiphanio
et al., 2008). This study shows that HO-1 overexpression blocks
the inflammatory response normally mounted against the liver
stage of infection, thus yielding a more permissive environment
for the parasite. In our hands, homozygous SR-BI/ mice in-
deed displayed liver HO-1 mRNA levels approximately 10-fold
(range of 3-fold to 20-fold) higher than those of wild-type mice,
consistent with the observations of Van Eck et al., and het-
erozygous SR-BI+/ mice showed no significant increase in
HO-1 levels compared to wild-type SR-BI+/+ mice (Figure 3C,
p < 0.001). As such, this would be expected to increase infection
rates vastly in homozygous SR-BI/ mice, thus likely counter-
acting or masking the predicted negative effects of SR-BI defi-
ciency. Interestingly, we observed significantly decreasedP. ber-
ghei infection rates in heterozygous SR-BI+/ mice (Figures 3D
and 3E, p < 0.001), whose HO-1 levels are similar to those of
wild-type SR-BI+/+ mice, whereas homozygous SR-BI/ mice,
whose HO-1 expression levels are greatly increased, showed in-
fection levels comparable to those of wild-type mice (Figure 3D).
This demonstrates that the SR-BI-related impairment of infection
was potent enough to fully counteract for the significant increase
in HO-1 expression in SR-BI/ mice. This observation was also
supported by results from mice deficient for PDZK1, which are
also known to exhibit nearly null levels of hepatic SR-BI (Kocher
et al., 2003). Like the SR-BI/ mice, PDZK1/ mice also
showed infection levels comparable to those of controls, despite
also having the elevated HO-1 expression expected to yield sig-
nificantly increased infection (Figure S8, p < 0.05). Nevertheless,
this does not rule out the possibility that other unknown factors,evier Inc.
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tion levels observed in these mice. Finally, the significantly al-
tered, pathological physiology ofSR-BI/mice may also include
long-term compensatory survival adaptations that provide the
parasite with alternative infection paths. Altogether, these results
unambiguously confirm the RNAi-based observations that SR-BI
indeed plays an important role in the liver stage of Plasmodium
infection in vivo.
Finally, we note that all of the above experiments were carried
out with P. berghei, whose natural preference for rodent hosts
entails the possibility that its infection strategy may differ in cer-
tain respects from that of human-pathogenic Plasmodium spe-
cies such as P. falciparum. The role of SR-BI was therefore
also tested for P. falciparum infection in human primary hepato-
cytes 72 hr after sporozoite addition, with the same qRT-PCR-
based assay of Plasmodium 18S RNA used above. Once again,
BLT-1 treatment of human primary hepatocytes caused a signif-
icant and specific decrease of P. falciparum infection in these
cells (Figure 3F, p < 0.001). Altogether, these data unequivocally
confirm the important role of host SR-BI expression in the
liver stage of Plasmodium infection not only in vitro but also
in vivo, and not only for the rodent malaria parasite, P. berghei,
but also for P. falciparum, the deadliest of human malarial
pathogens.
Figure 3. Host SR-BI Plays a Key Role
in P. berghei Infection In Vivo
(A and B) Effect of siRNA-mediated in vivo knock-
down of SR-BI on mouse liver stage (A) and blood
stage (B) infection by P. berghei. Liver infection
load ([A], black bars) was measured by qRT-PCR
analysis of P. berghei 18S rRNA normalized to
hypoxanthine-guanine phosphoribosyltransferase
(HPRT) in liver extracts taken 40 hr after sporozoite
i.v. injection, and plotted as percentage of the
mean of negative control samples (‘‘C’’). Grey
bars in (A) represent the remaining mRNA levels
for the targeted mSR-BI gene in the same liver
samples. Results are expressed as the mean ±
SD of five mice per group. Effect on blood stage
of treatment of oneSR-BI siRNA (B) was measured
by parasitemia (percentage of infected red blood
cells, iRBC) quantification with FACS. Mice treated
with a siRNA targeting luciferase were used as
control. Although all mice were positive in the con-
trol group by day 4 after sporozoite infection, only
two out of five mice were positive in the group
treated with SR-BI siRNA at day 4. All mice
became positive by day 5.
(C) HO-1 mRNA levels were measured in the livers
of infected SR-BI/, SR-BI+/, and wild-type
(SR-BI+/+) mice, collected 40 hr after sporozoite
i.v. injection. Results are expressed as the mean ±
SD of the results obtained for 12 wild-type (SR-BI+/+),
four SR-BI/, and nine SR-BI+/ mice.
(D and E) Level of liver P. berghei in vivo infection
was determined in SR-BI-deficient mice (D) by
qRT-PCR analysis of P. berghei 18S rRNA normal-
ized to HPRT in liver extracts taken 40 hr after
sporozoite i.v. injection and plotted as percentage
of the mean of control SR-BI wild-type mice
(SR-BI+/+). SR-BI wild-type (SR-BI+/+, n = 42), ho-
mozygous (SR-BI/, n = 9), and heterozygous
(SR-BI+/, n = 50) SR-BI-deficient mice are repre-
sented in black, white, and red circles, respec-
tively. Black bars represent the average of the
infection level in each experimental group. Com-
parison of the infection rate versus SR-BI mRNA
level in SR-BI+/+ and SR-BI+/ mice (in black and
red circles, respectively), measured by qRT-PCR,
shows a correlation between the infection rate and
the level of SR-BI expression in the liver (E).
(F) Host SR-BI plays a key role in infection of pri-
mary human hepatocytes by P. falciparum. Effect
of BLT-1 on P. falciparum infection in human primary hepatocytes was measured by qRT-PCR. BLT-1 was added to cells 1 hr before sporozoite addition,
and infection load was measured in cell extracts taken 72 hr after sporozoite addition, as described in the main text. Results are expressed as the mean ± SD
of triplicate samples.
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and Development of Plasmodium inside
the Parasitophorous Vacuole
Having established the basic effects of SR-BI inhibition on liver
infection both in vitro and in vivo, we next sought to gain further
mechanistic insights by dissecting the infection process into its
constituent steps. Hepatocyte infection by Plasmodium can be
conceptually viewed as comprising three consecutive steps:
cell traversal, productive hepatocyte invasion, and intracellular
development. Since our in vitro infection model enables us to
distinguish between these steps, we aimed to determine which
of these involved SR-BI function.
Over 95% of the infective sporozoites in our standard in vitro
assay described above have completed the traversal and inva-
sion steps at 2 hr after addition to the cells (Prudencio et al.,
2008). In order to quantify traversed versus invaded cells prior
to EEF development most accurately, we used a fluorescence-
Figure 4. Host SR-BI Plays a Role in Inva-
sion of P. berghei in Huh7 Cells
(A and B) FACS analysis of effects of siRNA-medi-
ated knockdown of SR-BI (black bars) or different
concentrations of BLT-1, BLT-2, and BLT-4 treat-
ment (gray bars) on invasion phase of infection in
Huh7 cells, with GFP-expressing P. berghei spo-
rozoites. As indicated in diagrams above the bar
charts, cells were harvested for flow cytometry
2 hr after sporozoite addition, and invasion rate
was measured as percentage of GFP+ cells com-
pared to control values. For siRNA-treated sam-
ples, control samples (Neg. C) were treated with
a nonspecific siRNA. For BLT-treated samples,
control (DMSO) was treated with drug dilution
buffer containing same level of DMSO found in the
most concentrated drug treatment. Results are
expressed as the mean ± SD of triplicate samples.
activated cell sorting (FACS)-based as-
say (Prudencio et al., 2008). In brief, Huh7
cells were infected with GFP-expressing
P. berghei sporozoites in the presence
of rhodamine-dextran. Two hours after
sporozoite addition, cells were harvested
and analyzed by FACS. Cells that had
been transiently traversed by sporozoites
were identified as rhodamine-dextran
positive, whereas cells successfully in-
vaded by sporozoites were identified by
the presence of GFP and the absence of
rhodamine-dextran (Mota et al., 2001)
(Figure S9). Pretreatments of the host
cells with three distinct SR-BI-targeting
siRNAs, as characterized above, did not
lead to any difference in the number of
traversed cells (Figure S9). Still, these
treatments yielded significant reductions
in the proportion of Huh7 cells invaded
by P. berghei sporozoites, as compared
to controls (Figure 4A, p < 0.001). Simi-
larly, treatment with BLT-1, BLT-2, or BLT-4 also led to a dose-
dependent decrease in invaded cells measured 2 hr after sporo-
zoite addition (Figure 4B). These results unambiguously reveal
a key role for SR-BI during the initial invasion step of sporozoite
infection.
We next examined whether SR-BI also has a role in the follow-
ing step of sporozoite infection, i.e., development of the EEF
within the parasitophorous vacuole. Pretreatments of the Huh7
cells with SR-BI-specific siRNAs, or exposure to blocking anti-
body or small molecule inhibitors (BLTs) throughout the full
24 hr infection period of our in vitro microscopy assay all yielded
marked decreases in EEF size, as measured with automated
image analysis algorithms (Figures 5A and 5B). The absence of
larger EEF size classes noted with this analysis suggested a pos-
sible blockage of EEF development. Detailed FACS analysis of
Huh7 cells infected with GFP-expressing P. berghei also re-
vealed this effect of BLT-1, BLT-2, and BLT-4 treatment on
276 Cell Host & Microbe 4, 271–282, September 11, 2008 ª2008 Elsevier Inc.
Cell Host & Microbe
Host SR-BI in Malaria Parasite Liver InfectionEEF development. This analysis showed that, in addition to the
marked decrease in number of infected cells already noted
2 hr after sporozoite addition (Figure 4B), a significant decrease
in GFP intensity becomes apparent within the infected cells
at the 24 hr or 48 hr time points (Figure 5C, Figures S10 and
S11). Altogether, these results are consistent with a defect in
P. berghei development as a result of SR-BI inhibition.
However, since invasion was also affected under the above
assay conditions, we conducted more precise tests to address
the development stage more unambiguously. We investigated
whether BLT-1, BLT-2, and BLT-4 retain their inhibitory effect
on infection when added only after completion of sporozoite in-
vasion, i.e., 2 hr after sporozoite addition to cells under our assay
conditions. When infection was measured 24 hr after sporozoite
addition, treated cells showed a drop in GFP intensity relative to
controls comparable to that observed after 24 hr exposure to
similar amounts of the same compounds (Figure 5C). This drop
was even more notable when infection was assessed 48 hr after
sporozoite addition (Figure S11). In a parallel experiment, sam-
ples were incubated with BLT-1, BLT-2, and BLT-4 for the first
2 hr after sporozoite addition and subsequently washed with
fresh medium. Infection was then measured by FACS 24 hr or
48 hr later. The results show that this treatment led not only to
the expected decrease in the proportion of infected cells due
to a reduced invasion but also to a drop in GFP intensity (Fig-
ure 5C and Figure S11). Together, these data indicate that host
liver cell SR-BI function is required not only for sporozoite inva-
sion but also for the subsequent development of EEFs within
the parasitophorous vacuole.
Next we aimed to gain mechanistic insights into the functional
contributions of SR-BI in both these steps of infection. With
regard to SR-BI’s observed role in the invasion step, one could
envisage that SR-BI might be fulfilling at least some receptor-
like functions for the sporozoite, mediating its initial binding
Figure 5. Host SR-BI Plays a Role in Devel-
opment of P. berghei in Huh7 Cells
(A) Representative pictures of EEFs in cells fixed
24 hr after sporozoite addition. Cell nuclei are
represented in red and EEFs in green. Automated
analysis of microscopy images enabled the classi-
fication of EEFs in four size classes defined within
the area ranges detailed in the grayscale color
code shown.
(B) Effect of siRNA-mediated knockdown of SR-BI
and different concentrations of BLT-1, BLT-2, and
BLT-4 treatment, as well as serial dilutions of a SR-
BI-blocking antibody on P. berghei development
within host Huh7 cells, as determined by EEF size
classification via automated analysis of micros-
copy images from cells fixed 24 hr after sporozoite
addition. Data shown are from the samples used
for infection rate analysis in Figure 2. Four classes
of EEF sizes are represented as different gray
levels used in bar fills, ranging from black for EEFs
with the smallest areas, up to lightest gray tone for
the largest EEFs. For siRNA-treated samples, con-
trol samples (Neg. C) were treated with a nonspe-
cific siRNA. For BLT-treated samples, control
samples (‘‘C’’) were treated with drug dilution
buffer containing same level of DMSO found in
most concentrated drug treatment. For samples
treated with SR-BI-blocking antibody, control
samples were exposed to antibody dilution buffer
containing same azide concentration present in
most concentrated antibody treatment. As indi-
cated in diagram above bar chart, cells were either
treated with siRNAs 48 hr before sporozoite addi-
tion or treated with the different BLT inhibitors
and the antibody 1 hr before sporozoite addition.
Results are expressed as the mean of triplicate
samples.
(C) Effect of BLT-1, BLT-2, and BLT-4 treatment on
P. berghei development within host Huh7 cells, as
measured by FACS in cells harvested at 24 hr after
addition of GFP-expressing sporozoites. Control
represents cells treated with drug dilution buffer
containing same level of DMSO found in drug treat-
ment. Drug incubation periods are indicated in the
diagrams above the charts. The graphs display
representative datasets of triplicate experimental
samples.
Cell Host & Microbe 4, 271–282, September 11, 2008 ª2008 Elsevier Inc. 277
Cell Host & Microbe
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ciated cholesterol or lipoprotein particles. To test these hypoth-
eses, we infected cultured human Huh7 hepatoma cells grown
in medium containing lipoprotein-deficient serum (LPDS) with
isolated P. berghei sporozoites in the presence of defined
amounts of human lipoproteins know to bind to SR-BI, namely
high-density lipoprotein (HDL), low-density lipoprotein (LDL),
acetylated LDL (acLDL), or oxidized LDL (oxLDL). Infection rates
were then quantified by fluorescence microscopy. Both modified
forms of LDL (modLDL) reproducibly reduced the infection levels
(p < 0.01 and p < 0.001 for concentrations equal or higher than
100 mg/ml of oxLDL and acLDL, respectively), whereas LDL or
HDL did not (Figure 6A). The expected inhibition of infection
was only observed when the added acLDL or oxLDL were pres-
ent during the first 2 hr after sporozoite addition to the cells, i.e.,
the invasion phase (Figure 6B, p < 0.001). These results strongly
suggest that elevated levels of exogenous modLDL reduce Plas-
modium infection of hepatoma cells primarily by inhibiting the
sporozoite invasion step. In addition, it also clearly shows that
none of the lipoproteins tested facilitate sporozoite entry, making
it unlikely that these lipoprotein particles play a bridging or ‘‘car-
rier’’ role for the invading sporozoites. In fact, our data suggest
that if SR-BI indeed acts as a receptor or coreceptor for sporo-
zoite invasion, it most likely does so through direct interactions
with the sporozoite, which are apparently susceptible to com-
petitive inhibition from modLDL. Nevertheless, the possibility
also exists that other receptors for modLDL may be present in
the vicinity of SR-BI, thereby influencing SR-BI-mediated para-
site invasion. These possibilities clearly warrant further analysis.
Beyond the invasion step, our results also show that SR-BI
plays an important role in EEF development. Inside hepatocytes,
Plasmodium sporozoites undergo a major transformation, with
each giving rise to thousands of merozoites, necessarily requir-
ing the availability of sufficient lipids for the synthesis of large
amounts of new membranes. It is therefore tempting to hypoth-
esize that our observations may reflect a direct involvement of
the host cell SR-BI’s selective lipid uptake activity in ‘‘feeding’’
cholesteryl esters and other lipids to the parasite across the par-
asitophorous vacuole membrane. Thus, we sought to determine
the parasite requirements for lipids from extracellular and
Figure 6. Mechanistic Insights into SR-BI
Roles in Infection
(A) Effect of different concentrations of LDL,
acLDL, oxLDL, and HDL on Huh7 cell infection
by P. berghei sporozoites. Results are expressed
as the mean ± SD of three independent infections.
(B) Quantification of infection of Huh7 cells incu-
bated with acLDL at various time points relative
to addition of P. berghei sporozoites. All infections
were measured 24 hr after sporozoite addition.
Results are expressed as the mean ± SD of three
independent infections.
(C) Effect of cholesterol depletion on Huh7 cell
infection by P. berghei sporozoites. LPDS, lipo-
protein-deficient serum; HC, hydroxycholesterol.
Control cells (‘‘C’’) were grown and infected in
the complete medium and in the absence of HC.
Results are expressed as the mean ± SD of three
independent infections.
(D) Effect of cholesterol depletion on P. berghei
development within host Huh7 cells, as deter-
mined by EEF size classification via automated
analysis of microscopy images from cells fixed
24 hr after sporozoite addition. Data shown are
from the samples used for infection rate analysis
in (C). Four classes of EEF sizes are represented
as different gray levels used in bar fills, ranging
from black for EEFs with the smallest areas up to
lightest gray tone for the largest EEFs. Control
cells (‘‘C’’) were grown and infected in the com-
plete medium and in the absence of HC.
(E) Immunofluorescence analysis of SR-BI locali-
zation in infected Huh7 cells fixed 24 hr after addi-
tion of P. berghei sporozoites. The plot represents
the quantification of the percentage of EEFs
(green) with different levels of SR-BI (red) in imme-
diate proximity, according to classification shown
in small images: a, high levels of SR-BI staining
in the proximity of the EEF; b, medium levels of
SR-BI staining in the proximity of the EEF; and c,
no SR-BI staining in the proximity of the EEF. Re-
sults are expressed as the mean ± SD of EEFs (%)
in three independent infections.
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rozoites were assayed in Huh7 hepatoma cells depleted of exter-
nal lipids via growth in LPDS medium, depleted of internal lipid
sources via hydroxycholesterol (HC) treatment, or depleted of
both by combining the two conditions. The results clearly show
that Huh7 infection by P. berghei sporozoites is significantly re-
duced only when both internal and external sources of lipids
are depleted, as shown by the quantification of EEF numbers by
microscopy (Figure 6C), as well as EEF size reductions (Fig-
ure 6D). Importantly, SR-BI staining can be observed in the
periphery of the parasitophorous vacuole of 79.5% ± 6.3% of in-
tracellular EEFs (Figure 6E), thus supporting roles at both the
cytoplasmic membrane as well as within the intracellular envi-
ronment to the developing EEF.
Host Cell SR-BI Constitutes a Natural Limiting Factor
for Plasmodium Sporozoite Infection
All the above results implicate SR-BI as an important factor for
both Plasmodium sporozoite invasion and EEF development in-
side host liver cells. It was therefore of clear interest to determine
in what capacity SR-BI might also represent a natural limiting
factor for infection. We tested this hypothesis by examining
whether transient overexpression of SR-BI could lead to an in-
crease in invasion and/or infection in cells such as HeLa that
are normally less permissive than Huh7 to Plasmodium sporozo-
ites. The same test was also carried out in Huh7 cells to deter-
mine in parallel whether their wild-type levels of SR-BI represent
a natural rate-limiting step for their own infectability. To this end,
Huh7 and HeLa cells, the latter of which normally express much
lower levels of SR-BI (as confirmed here in Figures 7A and 7B),
were transfected with a CMV promoter-driven, SR-BI-express-
ing plasmid and subjected to our P. berghei infection and inva-
sion assays as described above. The results clearly show that our
transient transfection yields the expected significant increase in
SR-BI expression in both Huh7 and HeLa cells, as detected both
at mRNA (Figure 7A) and protein levels (Figure 7B). In addition,
SR-BI-specific extracellular staining also shows that a significant
proportion of cells express SR-BI at their surface (Figure 7C),
consistent with the protein’s expected functionality. Importantly,
significant increases in P. berghei sporozoite infection and inva-
sion correlated clearly with SR-BI expression rise (Figures 7D
and 7E and Figure S12, p < 0.01). Moreover, inhibition of SR-BI
function with a synthetic inhibitor in overexpressing cells causes
infection rates to revert back down to levels comparable to those
of control cells treated with the same inhibitor (Figure S12). Thus,
taken together, these data add yet further support and confirma-
tion for the functional role of host SR-BI in sporozoite infection,
demonstrating that SR-BI function represents a natural limiting
factor controlling the susceptibility of otherwise refractory cells
to Plasmodium infection.
DISCUSSION
The present study adds significant new insights into the host
molecules and cellular processes underlying this parasite’s in-
fection of the liver. In particular, our results confirm and extend
earlier suggested links between liver infection and lipoprotein
pathways (Shakibaei and Frevert, 1996; Sinnis et al., 1996). By
using several types of inhibitors including RNAi both in vitro inCell Hostcultured human cells and in vivo in a mouse model of infection,
we have identified a major lipoprotein receptor, SR-BI, as a func-
tionally important host factor for both sporozoite invasion and
EEF development. SR-BI is a 509-amino acid, 82 kDa glycopro-
tein, with two cytoplasmic C- and N-terminal domains separated
by a large extracellular domain. It mediates the traffic of choles-
terol to and from lipoproteins, acting as the major receptor for
HDL, but also handling acLDL, oxLDL, and native LDL. SR-BI
expression is highest in tissues with critical roles in cholesterol
metabolism and is also expressed in a series of cell lines main-
tained in culture (reviewed in Rhainds et al., 2003).
Our present data support the conclusion that SR-BI defines a
preferred path, though not necessarily the only one, for liver infec-
tion by Plasmodium sporozoites. Indeed, the possibility of other
alternative, SR-BI-independent paths is formally suggested by
our observation that infection is still detectable in SR-BI null mice,
although the relevance of this result to less extreme physiological
contexts remains unclear. It is also notable thatP. berghei is more
promiscuous thanP. falciparum and has been shown to use alter-
native pathways of invasion depending on the cell type (Silvie
et al., 2007). Regardless, our findings of increased infection after
SR-BI overexpression in both Huh7 and the normally nonpermis-
sive HeLa further suggest that SR-BI represents a strongly en-
abling and naturally limiting factor for Plasmodium infection.
Our data also offer some mechanistic characterization of SR-
BI’s contributions to individual steps of the liver infection pro-
cess, revealing detectable roles in both the productive invasion
of host hepatocytes by sporozoites and in development of the
resulting EEFs. By placing these observations in the context of
SR-BI’s known functions in lipid transport, we have tested sev-
eral hypotheses that might account for SR-BI’s role in infection.
First, with regard to SR-BI’s observed role in the invasion step,
we have hypothesized that SR-BI might mediate the sporozoite’s
initial binding and entry into the cell either directly or indirectly,
through associated cholesterol or lipoprotein particles. Our re-
sults allow us to exclude the latter possibility, as addition of lipo-
proteins known to bind SR-BI either has no effect or leads to a
decrease rather than an increase in invasion. Thus, our data sug-
gest that if SR-BI indeed acts as a receptor or coreceptor during
invasion, it likely does so through direct interaction with the par-
asite in a manner that is vulnerable to competition from modLDL
forms but not from HDL. This is interesting from the point of view
that SR-BI domains involved in interactions with HDL and
modLDL forms have been shown to be separable (Gu et al.,
2000). The alternative possibility also remains that effective spo-
rozoite invasion requires a very specific balance in the host cell
plasma membrane’s lipid composition, which itself is directly
dependent upon SR-BI activity. Further in depth testing is under-
way to distinguish between these possibilities.
Beyond the invasion step, our results also show that SR-BI
plays an important role in EEF development. Inside hepatocytes,
Plasmodium sporozoites undergo a major transformation, with
each giving rise to thousands of merozoites. However, the spo-
rozoite’s requirements and the strategies it has developed to
survive and to be successful remain poorly understood (re-
viewed in Prudencio et al., 2006). Regardless, the parasite’s ex-
tensive proliferation during this stage necessarily requires the
availability of sufficient lipids for the synthesis of large amounts
of additional membranes. It is therefore tempting to hypothesize& Microbe 4, 271–282, September 11, 2008 ª2008 Elsevier Inc. 279
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cell SR-BI’s selective lipid uptake activity in ‘‘feeding’’ choles-
teryl esters and other lipids to the parasite. Our data show that
the depletion of all sources of cholesterol reduces infection, in-
cluding EEF development, whereas the complete absence of ex-
tracellular cholesterol alone, in form of lipoproteins, has no direct
impact on the latter. These observations indeed suggest that
SR-BI’s role in EEF development may result from its activity in
lipid transfer and that the intracellular stores of cholesterol, more
so than extracellular lipoproteins, are the source of the trans-
ferred cholesterol. Interestingly, immunofluorescence staining
of infected cells reveals an accumulation of SR-BI in the proximal
periphery of intracellular EEFs, supporting a possible role of this
molecule in providing cholesterol to the developing parasites.
Nevertheless, one should also consider the possibility that the
SR-BI effect may not necessarily be due to a direct transport
of cholesterol to the parasite but may instead result from other
roles of lipids on membrane organization and signaling. Although
Figure 7. Overexpression Studies Reveal
that Host SR-BI Plays a Role in Both Inva-
sion and Development of P. berghei in Per-
missive and Less-Permissive Cell Lines
(A and B) Effect of SR-BI overexpression on SR-BI
mRNA (A) and protein (B) levels in Huh7 and HeLa
cells, measured, respectively, by qRT-PCR and
semiquantitative western blotting of cell extracts
collected 48 hr after cell transfection from cells
transfected with a plasmid with the SR-BI gene
cloned (pSR-BI, in red) or with the same empty
plasmid (pØ, in black). Results are expressed as
the mean of triplicate samples ± SD and were nor-
malized to the control pØ of Huh7 cells (100%).
(C) Effect of SR-BI overexpression on intracellular
and surface SR-BI protein levels in Huh7 and HeLa
cells, measured by flow cytometry. The black and
red lines correspond to cells transfected with pØ
and pSR-BI and stained with an anti-SR-BI anti-
body labeled with phycoerythrin (a-SR-BI-PE),
whereas the gray area represents the negative
control of pØ unstained cells.
(D) Effect of SR-BI overexpression on Huh7 and
HeLa cells infection by GFP-expressing P. berghei
sporozoites, measured 24 hr after sporozoite
addition by flow cytometry. Bar code colors are
the same as above. Results are expressed as the
mean of triplicate samples ± SD and were normal-
ized to the control pØ of Huh7 cells (100%).
(E) Effect of SR-BI overexpression on invasion of
GFP-expressing P. berghei sporozoites within
Huh7 and HeLa cells, measured 2 hr after sporo-
zoite addition by flow cytometry. Bar and line
colors are the same as above. Results are ex-
pressed as the mean of triplicate samples ± SD
and were normalized to the control pØ of Huh7
cells (100%).
our results provide important evidence
for possible mechanisms underlying the
observed effects of SR-BI in Plasmodium
infection, more detailed analyses will be
required to further test the validity of the
different hypotheses.
Finally, it should be noted that, although the physiological
complications observed in the extreme context of the homozy-
gous SR-BI/ mice may warrant some caution in considering
sustained, long-term treatments of patients with SR-BI inhibi-
tors, such real-world pharmacological applications rarely come
close to achieving 100% loss of function of their target and are
therefore most likely to resemble the more benign physiology ob-
served in heterozygous SR-BI+/ mice and siRNA-treated mice.
Thus, the present study establishes an important proof of princi-
ple for the use of host factors as novel prophylactic or therapeu-
tic drug targets to combat malaria. In fact, targeting host compo-
nents offers major advantages over targeting the parasite itself,
including the inherently lower vulnerability of such drugs, used
either alone or in combination therapies, to the development of
resistance by the parasite (Cunha-Rodrigues et al., 2006). As
a second key advantage, the host factor approach also offers
significantly higher potential for accelerated drug discovery and
development through synergies with ongoing output from other
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Cell Host & Microbe
Host SR-BI in Malaria Parasite Liver Infectiondisease pipelines. This potential emerges particularly well in the
present case of SR-BI, which has recently been proposed to
function as a receptor for several pathogens, including hepatitis
C virus (HCV) (Scarselli et al., 2002), mycobacteria (Philips et al.,
2005), and bacteria (Vishnyakova et al., 2006). Interestingly, it
has been proposed that HCV requires functional cooperation be-
tween the host’s SR-BI and tetraspanin CD81, the latter having
also been implicated in Plasmodium sporozoite invasion (Silvie
et al., 2003, 2007). Thus, our present evidence, implicating host
SR-BI in malaria infection, may in fact help to advance our under-
standing of several other important infectious diseases. By fur-
ther exploring the parallels between these infection pathways,
one can now hope for increasing synergies between all of these
fields for years to come.
EXPERIMENTAL PROCEDURES
Cells and Parasites
Huh7 and HeLa cells were cultured, respectively, in supplemented RPMI and
Dulbecco’s modified Eagle’s medium (DMEM). Mouse and human primary
hepatocytes were obtained as previously described (Goncalves et al., 2007;
Mazier et al., 1985). Green fluorescent protein expressing P. berghei (parasite
line 259cl2) sporozoites (Franke-Fayard et al., 2004) or P. falciparum sporozo-
ites (NF 54 strain) were obtained from dissection of infected female Anopheles
stephensi mosquito salivary glands.
High-Throughput siRNA Screening of Plasmodium Infection
Huh7 cells were transfected 24 hr after being seeded with individual siRNAs, in
triplicate, in a final concentration of 100 nM per lipofection. Two days later,
cells were infected with P. berghei sporozoites and, 24 hr later, cells were fixed
and cell nuclei, filamentous actin, and EEFs were stained. Image acquisition
and analysis was performed automatically.
Gene-Specific Expression and Infection Quantification by qRT-PCR
For gene-specific expression in vitro, total RNA was isolated from Huh7 cells
48 hr after transfection. Relative amounts of remaining mRNA levels of RNAi
targets were calculated against the level of a housekeeping gene. Remaining
mRNA levels of RNAi-treated samples were compared with those of samples
transfected with negative unspecific siRNA. For infection determination in vivo
or ex vivo, total RNA was isolated from livers or primary hepatocytes, respec-
tively. The determination of liver parasite load was performed according to the
method developed for P. yoelii infections (Bruna-Romero et al., 2001).
Cell Treatment with an Anti-SR-BI Antibody, Chemical Compounds,
Lipoproteins, or Hydroxycholesterol
For SR-BI inhibition experiments, cells were incubated with an anti-SR-BI
antibody (NB 400-134, Novus Biologicals) or with the chemical compounds
BLT-1, BLT-2, BLT-4, or semicarbazone derivative of BLT-1 (BLT-1sc) (Chem-
Bridge). In lipoprotein competition experiments, Huh7 cells were incubated
with different concentrations of LDL, oxLDL, acLDL, and HDL (Biomedical
Technologies). In cholesterol depletion experiments, Huh7 cells were incu-
bated with 1 mM of hydroxycholesterol.
Fluorescence-Activated Cell Sorting Analysis
FACS analysis at 2, 24, and 48 hr after sporozoite addition was performed as
previously described (Prudencio et al., 2008).
In Vivo RNAi
C57Bl/6 mice were treated with a single i.v. administration of 5 mg/kg of siRNA
formulated in liposomal nanoparticles (Alnylam), as previously described
(Akinc et al., 2008). The sequences of the siRNAs used are shown in Table
S2. Thirty-six hours after siRNA administration, mice were infected with
P. berghei sporozoites. The remaining SR-BI mRNA levels and the parasite
load in the livers of infected mice were determined by qRT-PCR 40 hr after
sporozoite injection, 76 hr after siRNA administration. Interferon responseCell Hostand toxicity effects due to siRNA-treatment of mice were assessed by qRT-
PCR or biochemical analysis. SR-BI protein level in the liver was determined
by western blot, and the total cholesterol in the serum was determined bio-
chemically.
In Vivo Infection of SR-BI- and PDZK1-Deficient Mice
SR-BI-deficient (SR-BI/ and SR-BI/+), PDZK1/, and wild-type mice were
infected with 2 3 104 P. berghei sporozoites. Parasite load, SR-BI, and HO-1
mRNA levels in the liver of infected mice were determined by qRT-PCR 40 hr
after sporozoite injection. Total cholesterol in serum of infected mice was
biochemically determined by DNAtech (INETI, Portugal).
Effect of SR-BI Overexpression in P. berghei Infection
of Huh7 and HeLa Cells
Huh7 and HeLa cells were transfected in suspension with 1.5 mg of aSR-BI-ex-
pressing plasmid (pLPCx + SR-BI, Lavie and Dubuisson, Institut Pasteur de
Lille, France) with FuGENE 6 (Roche) according to the manufacturer’s instruc-
tions. As control, cells were transfected with an empty plasmid (pLPCx). Forty-
eight hours after transfection, SR-BI overexpression level was measured at the
mRNA and protein level by qRT-PCR and western blot, respectively. Intracel-
lular and surface SR-BI was measured by flow cytometry. P. berghei infection
was determined by flow cytometry at 2, 24, and 48 hr after sporozoite addition.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 12 figures,
and three tables and can be found online at http://www.cellhostandmicrobe.
com/cgi/content/full/4/3/271/DC1/.
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